MolDX: Breast Cancer Index® (BCI) Gene Expression Test

This contractor covers the Breast Cancer Index® (BCI) for postmenopausal women with invasive ER+ and/or PR+ and HER2- early-stage breast cancer (TNM T1-T3, pN0-pN1, M0) when the test will be used to inform chemotherapy decisions and/or assess late distant recurrence risk or endocrine responsiveness for extending endocrine therapy. Coverage is limited to non-metastatic (non-relapsed) disease and to situations where results will directly guide treatment management; patients not meeting these specific receptor, stage, menopausal status, or intended-use criteria are not covered.

"Coverage for the Breast Cancer Index® (BCI) is provided for postmenopausal women with invasive carcinoma of the breast that is estrogen receptor positive (ER+) and/or progesterone receptor positive..."

Sign up to see full coverage criteria, indications, and limitations.